Cyclooxygenase 2 pathway and its therapeutic inhibition in superantigen-induced toxic shock

Shock

Volumn 30, Issue 6, 2008, Pages 721-728

  Rajagopalan, Govindarajan ^a,d   Asmann, Yan W ^b   Lytle, Anna K ^a   Tilahun, Ashenafi Y ^a   Theuer, Jayne E ^a   Smart, Michele K ^a   Patel, Robin ^c   David, Chella S ^a  

^a Department of Immunology ^*

^b Division of Biomedical Informatics

^c Mayo Clinic

^d MAYO GRADUATE SCHOOL   (United States)

Author keywords

Cytokines; Rodents; T cell response; Toxic shock

Indexed keywords

3 (4 METHYLSULFONYLPHENYL) 4 PHENYL 5 TRIFLUOROMETHYLISOXAZOLE; CAY 10404; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GAMMA INTERFERON; HLA DR3 ANTIGEN; ICOSANOID; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; STAPHYLOCOCCUS ENTEROTOXIN B; SUPERANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPUTER PROGRAM; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME INHIBITION; ENZYME RELEASE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC MODEL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MICROARRAY ANALYSIS; MODULATION; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN BLOOD LEVEL; SPLEEN; T LYMPHOCYTE ACTIVATION; THYMOCYTE; TOXIC SHOCK SYNDROME; TRANSGENIC MOUSE; UPREGULATION;

ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYTOKINES; ENTEROTOXINS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; ISOXAZOLES; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SHOCK, SEPTIC; SULFONES; SUPERANTIGENS;

EID: 58149262953     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31817048f7     Document Type: Article

References (51)

1. Proft T, Fraser JD: Bacterial superantigens. Clin Exp Immunol 133:299-306, 2003.
2. Madsen JM: Toxins as weapons of mass destruction. A comparison and contrast with biological-warfare and chemical-warfare agents. Clin Lab Med 21:593-605, 2001.
3. Dinges MM, Orwin PM, Schlievert PM: Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 13:16-34, 2000. Table of contents.
4. McCormick JK, Yarwood JM, Schlievert PM: Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol 55:77-104, 2001.
5. Rajagopalan G, Sen M, Singh M, Murali N, Nath KA, Iijima K, Kita H, Leontovich AA, Unnikrishnan G, Patel R, et al.: Intranasal exposure to staphylococcal enterotoxin B elicits an acute systemic inflammatory response. Shock 25:647-656, 2006.
6. Rajagopalan G, Sen M, David CS: In vitro and in vivo evaluation of staphylococcal superantigen peptide antagonists. Infect Immun 72:6733-6737, 2004.
7. Rajagopalan G, Singh M, Sen M, Murali N, Nath KA, David CS: Endogenous superantigens shape response to exogenous superantigens. Clin Diagn Lab Immunol 12:1119-1122, 2005.
8. Rajagopalan G, Smart K, Murali N, Patel R, David CS: Acute systemic immune activation following vaginal exposure to staphylococcal enterotoxin B-implications for menstrual shock. J Reprod Immunol 73:51-59, 2007.
9. Rajagopalan G, Smart MK, Cheng S, Krco CJ, Johnson KL, David CS: Expression and function of HLA-DR3 and DQ8 in transgenic mice lacking functional H2-M. Tissue Antigens 62:149-161, 2003.
10. Rajagopalan G, Smart MK, Patel R, David CS: Acute systemic immune activation following conjunctival exposure to staphylococcal enterotoxin B. Infect Immun 74:6016-6019, 2006.
11. Turini ME, DuBois RN: Cyclooxygenase-2: a therapeutic target. Annu Rev Med 53:35-57, 2002.
12. Leach M, Hamilton LC, Olbrich A, Wray GM, Thiemermann C: Effects of inhibitors of the activity of cyclo-oxygenase-2 on the hypotension and multiple organ dysfunction caused by endotoxin: a comparison with dexamethasone. Br J Pharmacol 124:586-592, 1998.
13. 2 after trauma attenuates pro-inflammatory cytokines and improves survival. Shock 14:374-379, 2000.
14. Reddy RC, Chen GH, Tateda K, Tsai WC, Phare SM, Mancuso P, Peters- Golden M, Standiford TJ: Selective inhibition of COX-2 improves early survival in murine endotoxemia but not in bacterial peritonitis. Am J Physiol Lung Cell Mol Physiol 281:L537-543, 2001.
15. Tunctan B, Altug S, Uludag O, Demirkay B, Abacioglu N: Effects of cyclooxygenase inhibitors on nitric oxide production and survival in a mice model of sepsis. Pharmacol Res 48:37-48, 2003.
16. Pinheiro RM, Calixto JB: Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. Inflamm Res 51:603-610, 2002.
17. Habeeb AG, Knaus EE: Design and syntheses of diarylisoxazoles: novel inhibitors of cyclooxygenase-2 (COX-2) with analgesic-antiinflammatory activity. Drug Dev Res 51:273-286, 2000.
18. Yamanaka Y, Shiraki K, Inoue T, Miyashita K, Fuke H, Yamaguchi Y, Yamamoto N, Ito K, Sugimoto K, Nakano T: COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis. Int J Mol Med 18:41-47, 2006.
19. Katada J, Saito H, Ohashi A: Significance of cyclooxygenase-2 induced via p38 mitogen-activated protein kinase in mechanical stimulus-induced peritoneal adhesion in mice. J Pharmacol Exp Ther 313:286-292, 2005.
20. Fodera D, D'Alessandro N, Cusimano A, Poma P, Notarbartolo M, Lampiasi N, Montalto G, Cervello M: Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. Ann N Y Acad Sci 1028:440-449, 2004.
21. Parashar B, Latha Shankar S, Guin K, Butler J, Vikram B, Shafit-Zagardo B: Inhibition of human neuroblastoma cell growth by CAY10404, a highly selective COX-2 inhibitor. J Neurooncol 71:141-148, 2005.
22. Si J, Fu X, Behar J, Wands J, Beer DG, Souza RF, Spechler SJ, Lambeth D, Cao W: NADPH oxidase NOX5-S mediates acid-induced cyclooxygenase-2 expression via activation of NF-{kappa}B in Barrett's esophageal adenocarcinoma cells. J Biol Chem 282:16244-16255, 2007.
23. 2 production by Candida albicans. Infect Immun 75:3498-3505, 2007.
24. Wu Z, Irizarry RA: Preprocessing of oligonucleotide array data. Nat Biotechnol 22:656-658, 2004.
25. Wu Z, Irizarry RA, Gentleman R, Murillo FM, Spencer F: A Model Based Background Adjustment for Oligonucleotide Expression Arrays. Technical Report. Baltimore, MD: John Hopkins University, Department of Biostatistics Working Papers; 2003.
26. Reiner A, Yekutieli D, Benjamini Y: Identifying differentially expressed genes using false discovery rate controlling procedures. 10.1093/bioinformatics/ btf877. Bioinformatics 19:368-375, 2003.
27. Salomonis N, Hanspers K, Zambon AC, Vranizan K, Lawlor SC, Dahlquist KD, Doniger SW, Stuart J, Conklin BR, Pico AR: GenMAPP 2: new features and resources for pathway analysis. BMC Bioinformatics 8:217, 2007.
28. Murphy RC, Gijn MA: Biosynthesis and metabolism of leukotrienes. Biochem J 405:379-395, 2007.
29. Peters-Golden M, Brock TG: 5-Lipoxygenase and FLAP. Prostaglandins Leukol Essent Fatty Acids 69:99-109, 2003.
30. Xu L, Zhang L, Yi Y, Kang H-K, Datta SK: Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat Med 10:411 415. 2004.
31. Jendrossek V, Handrick R. Belka C: Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J 17:1547-1549. 2003.
32. Naoki Mori HI, Yoshida T. Tanabe T, Yamamoto N: Constitutive expression of the cyclooxygenase-2 gene in T-cell lines infected with human T cell leukemia virus type I. Int J Cancer 94:813-819. 2001.
33. Kishimoto H, Surh CD, Sprent J: A role for Fas in negative selection of thymocytes in vivo. J Exp Med 187:1427-1438, 1998.
34. Zhan Y, Purton JF, Godfrey DI, Cole TJ, Heath WR, Lew AM: Without peripheral interference, thymic deletion is mediated in a cohort of doublepositive cells without classical activation. Proc Natl Acad Sci U S A 100: 1197-1202,2003.
35. Brewer JA, Kanagawa O, Sleckman BP. Muglia LJ: Thymocyte apoptosis induced by T cell activation is mediated by glucocorticoids in vivo. J Immunol 169:1837-1843, 2002.
36. Iniguez MA. Punzon C, Fresno M: Induction of cyclooxygenase-2 on activated t lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors. J Immunol 163:111-119. 1999.
37. Iniguez MA, Martinez-Martinez S, Punzon C, Redondo JM, Fresno M: An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J Biol Chem 275:23627-23635, 2000.
38. Feldon SE, O'Loughlin CW, Ray DM, Landskroner-Eiger S, Seweryniak KE, Phipps RP: Activated human T lymphocytes express cyclooxygenase- 2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes. Am J Pathol 169:1183-1193, 2006.
39. Stapleton PP, Freeman TA, Monroy MA, Daly JM: Genetic ablation of iNOS modulates pro-inflammatory cytokine levels after trauma and confers a survival advantage following infectious challenge. J Am Coll Surg. 199:44. 2004. Surgical Forum Abstracts 2004 Clinical Congress.
40. Johnson PM, Vogt SK. Burney MW. Muglia LJ: COX-2 inhibition attenuates anorexia during systemic inflammation without impairing cytokine production. Am J Physiol Endocrinol Metah 282:E650-E656. 2002.
41. Gilroy DW. Colville-Nash PR, Willis D. Chivers J. Paul-Clark MJ. Willoughby DA: Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5:698-701. 1999.
42. 2 is a potent inhibitor of human interleukin 12 production. J Exp Med 181:775-779. 1995.
43. Harris SG. Padilla J, Koumas L, Ray D. Phipps RP: Prostaglandins as modulators of immunity. Trends Immunol 23:144-150. 2002.
44. Haas AR, Sun J. Vachani A. Wallace AF. Silverberg M. Kapoor V. Albelda SM: Cyclooxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res 12:214-222. 2006.
45. Sharma S, Zhu L, Yang SC. Zhang L. Lin J. Hillinger S. Gardner B. Reckamp K. Strieter RM. Huang M, et al.: Cyclooxygenase 2 inhibition promotes IFN- {gamma}-dependent enhancement of antitumor responses. J Immunol 175: 8L3-8I9. 2005.
46. H1 polarization in response to Helicobacter pylori. J Immunol 171:3913-3917. 2003.
47. 2 mediate the protective effects of cyclooxygena.se-2 in a mouse model of immune-mediated liver injury. Hepatology 45:159-169. 2007.
48. Schildknecht S, Bachschmid M. Baumann A. Ullrich V: COX-2 inhibitors selectively block prostacyclin synthesis in endotoxin exposed vascular smooth muscle cells. FASEB J 18:757-759. 2004.
49. Zardi EM. Zardi DM. Dobrina A, Afeltra A: Prostacyclin in sepsis: a systematic review. Prostaglandins Other Lipid Mediat 83:1-24. 2(K)7.
50. Patel NSA. Cuzzocrea S. Collino M. Chaterjee PK, Mazzon E. Britti D, Yaqoob MM. Thiemermann C: The role of cyclooxygenase-2 in the rodent kidney following ischaemia/reperfusion injury in vivo. Eur J Pharmacol 562: 148-154. 2007.
51. Bueno C. Criado G, McCormick JK, Madrenas J: T cell signalling induced by bacterial superantigens. Chem Immunol Allergy 93:161-180. 2(X)7.